Amir Nashat insider trades
Open-market stock purchases and sales by Amir Nashat, Director, 10% Owner at Camp4 Therapeutics Corp, from SEC Form 4 filings since May 14, 2013.
Track record: 36% of 11 scored buys are up 5% or more since purchase, averaging +10%.
Recent trades
| Date | Stock | Trade | Value |
|---|---|---|---|
| Jun 10, 2026 | CAMP Camp4 Therapeutics Corp | Bought (not open market) | — |
Companies traded
- CAMP Camp4 Therapeutics Corp: 3 buys, last Jun 10, 2026
- MORF Morphic Holding, Inc: 2 buys, 2 sales, last Aug 16, 2024
- SRRK Scholar Rock Holding Corp: 6 buys, last May 9, 2024
- SYRS Syros Pharmaceuticals, Inc: 2 buys, last Jun 1, 2022
- MTCR Metacrine, Inc: 2 buys, last May 18, 2022
- FATE Fate Therapeutics Inc: 4 buys, 63 sales, last Aug 1, 2019
- SELB Selecta Biosciences Inc: 4 buys, 20 sales, last Jun 14, 2019
- LIFE aTYR PHARMA Inc: other filings, last May 15, 2018
- BIND BIND Therapeutics, Inc: other filings, last Jun 9, 2015
- RCPT Receptos, Inc: 1 buy, 18 sales, last Jun 3, 2014